Prosecution Insights
Last updated: September 27, 2026
Application No. 18/706,816

NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF

Non-Final OA §102
Filed
May 02, 2024
Priority
Nov 10, 2021 — CN PCT/CN2021/129722 +3 more
Examiner
SCHMIDT, IZABELA MARIA
Art Unit
Tech Center
Assignee
Allianthera Boston Inc.
OA Round
1 (Non-Final)
65%
Grant Probability
Favorable
1-2
OA Rounds
10m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 65% — above average
65%
Career Allowance Rate
66 granted / 101 resolved
+5.3% vs TC avg
Strong +42% interview lift
Without
With
+42.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
32 currently pending
Career history
128
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
33.8%
-6.2% vs TC avg
§102
20.0%
-20.0% vs TC avg
§112
18.1%
-21.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 101 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Instant application 18/706,816 filed on 05/02/2024 claims benefit as follows: CONTINUING DATA: PNG media_image1.png 34 348 media_image1.png Greyscale PNG media_image2.png 12 248 media_image2.png Greyscale Status of the Application Claims 1, 2, 5, 6, 17, 20, 25, 28, 30, 33, 36-43, 45, 46 and 48 are pending. Information Disclosure Statement The information disclosure statement (IDS) submitted on 05/02/2024 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Election/Restrictions Applicant’s election without traverse of Group I in the reply filed on 07/20/2026 is acknowledged. Claims 45, 46 and 48 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 07/20/2026. Regarding species election, Applicant’s election without traverse of Compound A112 in the reply filed on 07/20/2026 is acknowledged. PNG media_image3.png 264 645 media_image3.png Greyscale It should be noted that Z is a substituted phenyl (substituted with F). Claim 33 is directed to a compound of claim 30 wherein Z is an unsubstituted phenyl group or an unsubstituted pyridyl. Therefore, claim 33 does not read on the elected species (claim 36 reciting substituted phenyl reads on the elected species). Claims 5, 17, 20, 25, 28, 33, 40, 42 and 43 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 07/20/2026. Examination will begin with the elected species. In accordance with the MPEP 803.02, if upon examination of the elected species, no prior art is found that would anticipate or render obvious the instant invention based on the elected species, the search of the Markush-type claim will be extended. If prior art is then found that anticipates or renders obvious the non-elected species, the Markush-type claim will be rejected. It should be noted that the prior art search will not be extended unnecessarily to cover all non-elected species. Should Applicant overcome the rejection by amending the claim, the amended claim will be reexamined. Id. The prior art search will be extended to the extent necessary to determine patentability of the Markush-type claim. Id. In the event prior art is found during reexamination that renders obvious or anticipates the amended Markush-type claim, the claim will be rejected and the action made final. Id. As per MPEP 803.02, the Examiner will attempt to determine whether the entire scope of the claims is patentable. Applicants' elected species, as shown above, does make a contribution over the prior art. Therefore, according to MPEP 803.02: should the elected species appear allowable; the search of the Markush-type claim will be extended. The search and examination should be continued until either (1) prior art is found that anticipates or renders obvious a species that falls within the scope of a proper Markush grouping that includes the elected species, or (2) it is determined that no prior art rejection of any species that falls within the scope of a proper Markush grouping that includes the elected species can be made. The Examiner need not extend the search beyond a proper Markush grouping. Species Election A careful review of the prior art has indicated that elected species is free of the prior art. A claim directed to the elected species in independent form would be free of prior art. The examiner has moved onto alternative species embodied within the general formula recited in instant claim 1, and subsequent examination is based on this species expansion. The whole scope of claim 1 has not been searched. Claim Objections Claim 41 is objected to for including unnecessary reference to the specification. MPEP 2173.05(s) states: “Where possible, claims are to be complete in themselves. Incorporation by reference to a specific figure or table "is permitted only in exceptional circumstances where there is no practical way to define the invention in words and where it is more concise to incorporate by reference than duplicating a drawing or table into the claim. Incorporation by reference is a necessity doctrine, not for applicant’s convenience." Ex parte Fressola, 27 USPQ2d 1608, 1609 (Bd. Pat. App. & Inter. 1993)”. The structures of the recited compounds could be readily and practically listed in claim 41. Alternatively, chemicals names may be added into the claim. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1, 2, 6, 30, 36, 37 and 38 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by WO2017/003902A1 (the reference has been provided with the previous office action). WO2017/003902A1 teaches and claims a method of treating a disease (see claim 12): PNG media_image4.png 73 666 media_image4.png Greyscale WO2017/003902A1 (see paragraph [0081], page 27) teaches: PNG media_image5.png 109 169 media_image5.png Greyscale that falls under instant Formula (I) PNG media_image6.png 122 80 media_image6.png Greyscale wherein R1 is C(=O)C1alkyl, R2 is OH, X1 is C-OH, A is PNG media_image7.png 62 34 media_image7.png Greyscale , Y is O, and Z is substituted phenyl group. Claims 1, 2, 6, 30, 36, 37 and 38 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by STN (RN 1980011-90-2, entered to STN 25 Aug 2016) STN teachers: PNG media_image8.png 774 971 media_image8.png Greyscale The above compound falls under instant Formula (I) PNG media_image6.png 122 80 media_image6.png Greyscale wherein R1 is C1alkyl, R2 is N(RN1)2, RN1 is H, X1 is C-OH, A is PNG media_image7.png 62 34 media_image7.png Greyscale , Y is O, and Z is substituted phenyl group. Regarding claims 37 and 38, it should be noted that Z (phenyl) is substituted with OH, C1alkyl and N(RN1)2 wherein each RN1 is H. The above compound was entered into STN on August 25, 2016. MPEP 2128 (I)(B) states “Electronic publications on the internet or on an online database are considered to be publicly available as of the date the item was publicly posted”. Allowable Subject Matter Claim 39 is objected to as being dependent upon a rejected base claim but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to IZABELA SCHMIDT whose telephone number is (703)756-4787. The examiner can normally be reached Monday - Friday from 9 am to 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton A Brooks can be reached at (571)270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GEORGE W KOSTURKO/Primary Examiner, Art Unit 1621 /I.S./Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

May 02, 2024
Application Filed
Sep 03, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12740990
COMPOSITION CONTAINING HOMOHARRINGTONINE AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MUSCLE DISEASES
2y 10m to grant Granted Sep 22, 2026
Patent 12715868
SMARCA2-VHL DEGRADERS
4y 2m to grant Granted Aug 25, 2026
Patent 12708610
PROTECTION OF POLYUNSATURATED FATTY ACIDS FROM RUMINAL DEGRADATION
3y 10m to grant Granted Aug 18, 2026
Patent 12685777
Compositions, Systems, and Methods for Modulating a Target Gene
1y 8m to grant Granted Jul 21, 2026
Patent 12662478
ATF6 MODULATORS AND USES THEREOF
4y 2m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+42.5%)
3y 3m (~10m remaining)
Median Time to Grant
Low
PTA Risk
Based on 101 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month